Company profile: Imegen
1.1 - Company Overview
Company description
- Provider of biomedical services and products for genetic analysis, offering diagnostic, prognostic, and preventive genetic services to improve health and quality of life, with the aim of being a worldwide reference in human genetics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Imegen
Therachon
HQ: Switzerland
Website
- Description: Provider of biotechnology-based medicines for rare genetic diseases with no available treatments, including TA-46, a novel protein therapy in development for achondroplasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therachon company profile →
Healx
HQ: United Kingdom
Website
- Description: Provider of AI-driven rare disease drug discovery and development, leveraging generative AI and machine learning to identify and repurpose drug candidates. Offerings include Healnet, preclinical testing, clinical trials, regulatory approval and access, and making approved treatments available to patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Healx company profile →
Soligenix
HQ: United States
Website
- Description: Provider of vaccines and therapeutics for biodefense and rare diseases, including HyBryte photodynamic therapy for cutaneous T-cell lymphoma; SGX302 light therapy for psoriasis; SGX942 IV dusquetide for severe oral mucositis in cancer patients; RiVax in-development ricin vaccine using ThermoVax thermal stabilization; and SGX943 dusquetide to reduce inflammation, eliminate infection, and enhance tissue healing in infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Soligenix company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
Entrada Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary EEV platform to target and engage typically inaccessible intracellular disease targets, with therapeutic programs using EEV-oligonucleotides. Pipeline includes Duchenne muscular dystrophy candidates ENTR-601-44, ENTR-601-45 and ENTR-601-50 for exon skipping to restore dystrophin, and a myotonic dystrophy type 1 program to restore MBNL protein activity in collaboration with Vertex.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entrada Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Imegen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Imegen
2.2 - Growth funds investing in similar companies to Imegen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Imegen
4.2 - Public trading comparable groups for Imegen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →